MARCH 2025LIFE SCIENCES REVIEW6The global life sciences market is growing rapidly due to technological advancements and increased investments. In 2023, the U.S. life science market was valued at $56.61 billion, with a projected CAGR of 9.3% from 2024 to 2030. Similarly, the global market is expected to expand from $17.95 billion in 2024 to $43.86 billion by 2032 at a CAGR of 11.8%.The integration of artificial intelligence (AI) in drug discovery is transforming life sciences by accelerating drug candidate identification. AI-driven platforms analyze vast datasets to predict molecule interactions, reducing research timelines and costs. Alongside AI, CRISPR gene-editing technology enables precise DNA modifications, allowing scientists to correct genetic mutations and improve cancer therapies. In line with various industry developments, we are featuring Creative BioTherapeutics, the Cancer Drug Resistance Company of the Year, in this edition.Beyond genetic innovations, manufacturing is evolving with single-use bioreactors, replacing traditional systems to lower contamination risks, cut costs and improve production flexibility, which aligns with the work of single-use bioreactors company of the year showcased in this edition.In clinical research, digital twin technology streamlines drug development with virtual patient models, enhancing trial efficiency. Meanwhile, the Boutique Marketing Communications Agency highlighted in this edition is driving industry awareness, which helps companies communicate innovations effectively.The edition also features thought leadership from industry experts, including Erick Morris, senior director, of translational research, oncology at Bristol Myers Squibb, who explores how translational research accelerates drug development by leveraging biomarkers, optimizing clinical transitions and aligning regulatory strategies. Another thought leader, Haichen Yang, vice president, clinical research at Amicus Therapeutics, discusses overcoming gene therapy bottlenecks by addressing regulatory, safety and manufacturing challenges to drive therapeutic advancements.We are showcasing the top companies in the life sciences space, highlighting their impact on cancer drug resistance, marketing communications and single-use bioreactors.We hope this edition of Life Science Review helps you explore innovations shaping the future of pharmaceutical advancements.EDITORIALBreakthroughs in Drug Resistance and BioreactorsCopyright © 2025 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsMARCH - 2025, Vol 06, Issue - 05 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersEmail:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.comAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoCelestial JordanRobert Grey Smith
< Page 5 | Page 7 >